Do analysts recommend INKT or LSTA?

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 204.48%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is INKT or LSTA more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Lisata Therapeutics N/A -116.08% -90.55%

Do analysts prefer LSTA or IMMP?

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,565.15%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, LSTA or IMMP?

Lisata Therapeutics has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lisata Therapeutics $170K 81.62 -$16.59M -$1.64 N/A Prima BioMed $16.40M 2.97 -$53.82M N/A N/A

Is LSTA or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -116.08% -90.55% Prima BioMed N/A N/A N/A

Do analysts recommend LSTA or CELU?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TIL or LSTA?

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 2.91%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is TIL or LSTA more profitable?

Instil Bio's return on equity of -26.78% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Lisata Therapeutics N/A -116.08% -90.55%

Do analysts rate MCRB or LSTA?

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 269.57%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Lisata Therapeutics (LSTA) Competitors

$1.54 -0.02 (-1.28%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.02 (-1.49%)

As of 09/15/2026 07:02 PM Eastern

Compare

LSTA vs. INKT, IMMP, CELU, TIL, and MCRB

Should you buy Lisata Therapeutics stock or one of its competitors? Lisata Therapeutics's main competitors and comparable companies include MiNK Therapeutics (INKT), Prima BioMed (IMMP), Celularity (CELU), Instil Bio (TIL), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lisata Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

MiNK Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Lisata Therapeutics	N/A	-116.08%	-90.55%

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics has higher earnings, but lower revenue than Lisata Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Lisata Therapeutics	$170K	81.62	-$16.59M	-$1.64	N/A

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 204.48%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 1.89 beat MiNK Therapeutics' score of 0.88 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Lisata Therapeutics	Very Positive

MiNK Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Summary

Lisata Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Lisata Therapeutics compare to Prima BioMed?

Lisata Therapeutics (NASDAQ:LSTA) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Lisata Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Lisata Therapeutics has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	81.62	-$16.59M	-$1.64	N/A
Prima BioMed	$16.40M	2.97	-$53.82M	N/A	N/A

Prima BioMed's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Prima BioMed	N/A	N/A	N/A

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,565.15%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Prima BioMed had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Prima BioMed and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.89 beat Prima BioMed's score of -0.04 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Prima BioMed	Neutral

Summary

Prima BioMed beats Lisata Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Lisata Therapeutics compare to Celularity?

Lisata Therapeutics (NASDAQ:LSTA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Celularity had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.89 beat Celularity's score of 0.44 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Celularity	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lisata Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Lisata Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Celularity	-345.45%	N/A	-77.94%

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lisata Therapeutics has higher earnings, but lower revenue than Celularity. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	81.62	-$16.59M	-$1.64	N/A
Celularity	$26.55M	1.35	-$91.72M	-$3.33	N/A

Summary

Lisata Therapeutics and Celularity tied by winning 7 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.89 equaled Lisata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Instil Bio	Very Positive
Lisata Therapeutics	Very Positive

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lisata Therapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Lisata Therapeutics	$170K	81.62	-$16.59M	-$1.64	N/A

Instil Bio's return on equity of -26.78% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 2.91%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Instil Bio beats Lisata Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Lisata Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Seres Therapeutics and Seres Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 1.89 beat Seres Therapeutics' score of 0.93 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Positive
Lisata Therapeutics	Very Positive

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Seres Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 269.57%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lisata Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Seres Therapeutics has higher revenue and earnings than Lisata Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	58.52	$5.70M	-$2.43	N/A
Lisata Therapeutics	$170K	81.62	-$16.59M	-$1.64	N/A

Summary

Seres Therapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.06M	$3.89B	$7.20B	$15.01B
Dividend Yield	N/A	3.65%	2.57%	12.21%
P/E Ratio	-0.94	14.11	272.86	25.31
Price / Sales	81.62	1,434.33	701.69	107.99
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	0.93	15.17	10.37	6.18
Net Income	-$16.59M	-$22.78M	$3.49B	$357.96M
7 Day Performance	-18.95%	-0.71%	-0.76%	-0.56%
1 Month Performance	41.28%	0.29%	-0.39%	-3.62%
1 Year Performance	-33.04%	39.41%	18.93%	6.05%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	1.1238 of 5 stars	$1.54 -1.3%	N/A	-27.4%	$14.06M	$170K	N/A	30
INKT MiNK Therapeutics	2.327 of 5 stars	$11.33 +3.5%	$35.00 +208.9%	-19.4%	$55.88M	N/A	N/A	30	Gap Down
IMMP Prima BioMed	1.5652 of 5 stars	$0.38 +3.2%	$5.50 +1,336.4%	-80.9%	$54.71M	$6.69M	N/A	2,021	Gap Up
CELU Celularity	0.2978 of 5 stars	$1.86 -1.1%	$6.00 +222.6%	-43.4%	$54.42M	$26.55M	N/A	220
TIL Instil Bio	1.2049 of 5 stars	$7.68 -0.1%	$66.00 +759.4%	-72.0%	$52.15M	N/A	N/A	410	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. INKT, IMMP, CELU, TIL, and MCRB

How does Lisata Therapeutics compare to MiNK Therapeutics?

Summary

How does Lisata Therapeutics compare to Prima BioMed?

Summary

How does Lisata Therapeutics compare to Celularity?

Summary

How does Lisata Therapeutics compare to Instil Bio?

Summary

How does Lisata Therapeutics compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. INKT, IMMP, CELU, TIL, and MCRB

How does Lisata Therapeutics compare to MiNK Therapeutics?

Is INKT or LSTA more profitable?

Do insiders & institutionals hold more shares of INKT or LSTA?

Which has preferable valuation and earnings, INKT or LSTA?

Do analysts recommend INKT or LSTA?

Does the media refer more to INKT or LSTA?

Which has more volatility and risk, INKT or LSTA?

Summary

How does Lisata Therapeutics compare to Prima BioMed?

Which has more risk and volatility, LSTA or IMMP?

Which has better valuation and earnings, LSTA or IMMP?

Is LSTA or IMMP more profitable?

Do institutionals and insiders hold more shares of LSTA or IMMP?

Do analysts prefer LSTA or IMMP?

Does the media prefer LSTA or IMMP?

Summary

How does Lisata Therapeutics compare to Celularity?

Does the media prefer LSTA or CELU?

Do analysts recommend LSTA or CELU?

Which has more volatility and risk, LSTA or CELU?

Is LSTA or CELU more profitable?

Do insiders & institutionals believe in LSTA or CELU?

Which has better earnings & valuation, LSTA or CELU?

Summary

How does Lisata Therapeutics compare to Instil Bio?

Which has more risk and volatility, TIL or LSTA?

Does the media refer more to TIL or LSTA?

Do institutionals & insiders believe in TIL or LSTA?

Which has higher earnings and valuation, TIL or LSTA?

Is TIL or LSTA more profitable?

Do analysts prefer TIL or LSTA?

Summary

How does Lisata Therapeutics compare to Seres Therapeutics?

Does the media favor MCRB or LSTA?

Do insiders and institutionals have more ownership in MCRB or LSTA?

Which has more risk and volatility, MCRB or LSTA?

Do analysts rate MCRB or LSTA?

Is MCRB or LSTA more profitable?

Which has preferable valuation and earnings, MCRB or LSTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools